SGMO - Sangamo Therapeutics GAAP EPS of -$0.29 beats by $0.06 revenue of $29.38M beats by $4.75M
- Sangamo Therapeutics press release ( NASDAQ: SGMO ): Q2 GAAP EPS of -$0.29 beats by $0.06 .
- Revenue of $29.38M (+5.3% Y/Y) beats by $4.75M .
- Financial Guidance for 2022 Reiterated (initial guidance provided on February 24, 2022).
- On a GAAP basis, SGMO continue to expect total operating expenses in the range of approximately $320 million to $350 million in 2022, which includes non-cash stock-based compensation expense.
- SGMO continues to expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $40 million, in the range of approximately $280 million to $310 million in 2022.
For further details see:
Sangamo Therapeutics GAAP EPS of -$0.29 beats by $0.06, revenue of $29.38M beats by $4.75M